메뉴 건너뛰기




Volumn 47, Issue 4, 2016, Pages 308-312

DRCR Protocol-T: Reconciling 1- and 2-year data for managing diabetic macular edema

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; DEXAMETHASONE; FLUOCINOLONE; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

EID: 84983740561     PISSN: 23258160     EISSN: 23258179     Source Type: Journal    
DOI: 10.3928/23258160-20160324-01     Document Type: Short Survey
Times cited : (8)

References (28)
  • 1
    • 84975856269 scopus 로고    scopus 로고
    • Economic costs of diabetes in the U.S. in 2012
    • American Diabetes Association
    • American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013;36(4):1033-1046.
    • (2013) Diabetes Care , vol.36 , Issue.4 , pp. 1033-1046
  • 2
    • 84941702063 scopus 로고    scopus 로고
    • Prevalence of and trends in diabetes among adults in the United States, 1988-2012
    • Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and trends in diabetes among adults in the United States, 1988-2012. JAMA. 2015;314(10):1021-1029.
    • (2015) JAMA , vol.314 , Issue.10 , pp. 1021-1029
    • Menke, A.1    Casagrande, S.2    Geiss, L.3    Cowie, C.C.4
  • 3
    • 84862619470 scopus 로고    scopus 로고
    • Prevalence of diabetic retinopathy in various ethnic groups: A worldwide perspective
    • Sivaprasad S, Gupta B, Crosby-Nwaobi R, Evans J. Prevalence of diabetic retinopathy in various ethnic groups: a worldwide perspective. Surv Ophthalmol. 2012;57(4):347-370.
    • (2012) Surv Ophthalmol , vol.57 , Issue.4 , pp. 347-370
    • Sivaprasad, S.1    Gupta, B.2    Crosby-Nwaobi, R.3    Evans, J.4
  • 4
    • 77953555650 scopus 로고    scopus 로고
    • Burden of illness of diabetic macular edema: Literature review
    • Chen E, Looman M, Laouri M, et al. Burden of illness of diabetic macular edema: literature review. Curr Med Res Opin. 2010;26(7):1587-1597.
    • (2010) Curr Med Res Opin , vol.26 , Issue.7 , pp. 1587-1597
    • Chen, E.1    Looman, M.2    Laouri, M.3
  • 5
    • 84863320414 scopus 로고    scopus 로고
    • Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results
    • Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388-1398.
    • (2012) Ophthalmology , vol.119 , Issue.7 , pp. 1388-1398
    • Martin, D.F.1    Maguire, M.G.2
  • 6
    • 84886430519 scopus 로고    scopus 로고
    • Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-Year findings of the IVAN randomised controlled trial
    • Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013;382(9900):1258-1267.
    • (2013) Lancet , vol.382 , Issue.9900 , pp. 1258-1267
    • Chakravarthy, U.1    Harding, S.P.2    Rogers, C.A.3
  • 7
    • 84891631034 scopus 로고    scopus 로고
    • Intravitreal aflibercept injection for neovascular age-related macular degeneration: Ninety-six-week results of the VIEW studies
    • Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121(1):193-201.
    • (2014) Ophthalmology , vol.121 , Issue.1 , pp. 193-201
    • Schmidt-Erfurth, U.1    Kaiser, P.K.2    Korobelnik, J.F.3
  • 8
    • 84925423332 scopus 로고    scopus 로고
    • Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema
    • Diabetic Retinopathy Clinical Research Network
    • Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193-1203.
    • (2015) N Engl J Med , vol.372 , Issue.13 , pp. 1193-1203
    • Wells, J.A.1    Glassman, A.R.2
  • 9
    • 84975698767 scopus 로고    scopus 로고
    • Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: Two-year results from a comparative effectiveness randomized clinical trial
    • Epub ahead of print
    • Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016; [Epub ahead of print]. doi: 10.1016/j.ophtha.2016.02.022.
    • (2016) Ophthalmology
    • Wells, J.A.1    Glassman, A.R.2    Ayala, A.R.3
  • 10
    • 84941287133 scopus 로고    scopus 로고
    • Comparative effectiveness trial for diabetic macular edema: Three comparisons for the price of 1 study from the Diabetic Retinopathy Clinical Research Network
    • Jampol LM, Glassman AR, Bressler NM. Comparative effectiveness trial for diabetic macular edema: three comparisons for the price of 1 study from the Diabetic Retinopathy Clinical Research Network. JAMA Ophthalmol. 2015;133(9):983-984.
    • (2015) JAMA Ophthalmol , vol.133 , Issue.9 , pp. 983-984
    • Jampol, L.M.1    Glassman, A.R.2    Bressler, N.M.3
  • 12
    • 84870723704 scopus 로고    scopus 로고
    • Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
    • Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537-2548.
    • (2012) Ophthalmology , vol.119 , Issue.12 , pp. 2537-2548
    • Heier, J.S.1    Brown, D.M.2    Chong, V.3
  • 13
    • 77949352911 scopus 로고    scopus 로고
    • Prospective evaluation of visual acuity assessment: A comparison of snellen versus ETDRS charts in clinical practice (An AOS Thesis)
    • Kaiser PK. Prospective evaluation of visual acuity assessment: a comparison of snellen versus ETDRS charts in clinical practice (An AOS Thesis). Trans Am Ophthalmol Soc. 2009;107:311-324.
    • (2009) Trans Am Ophthalmol Soc , vol.107 , pp. 311-324
    • Kaiser, P.K.1
  • 14
    • 84862847569 scopus 로고    scopus 로고
    • Time to first treatment: The significance of early treatment of exudative age-related macular degeneration
    • Rauch R, Weingessel B, Maca SM, et al. Time to first treatment: The significance of early treatment of exudative age-related macular degeneration. Retina. 2012;32(7):1260-1264.
    • (2012) Retina , vol.32 , Issue.7 , pp. 1260-1264
    • Rauch, R.1    Weingessel, B.2    Maca, S.M.3
  • 15
    • 84872072339 scopus 로고    scopus 로고
    • Anatomical measures as predictors of visual outcomes in ranibizumab-treated eyes with neovascular age-related macular degeneration
    • Brown DM, Tuomi L, Shapiro H, Pier Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab-treated eyes with neovascular age-related macular degeneration. Retina. 2013;33(1):23-34.
    • (2013) Retina , vol.33 , Issue.1 , pp. 23-34
    • Brown, D.M.1    Tuomi, L.2    Shapiro, H.3
  • 16
    • 79958843614 scopus 로고    scopus 로고
    • Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: Twelve-month outcomes of a phase III study
    • Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology. 2011;118(10):2041-2049.
    • (2011) Ophthalmology , vol.118 , Issue.10 , pp. 2041-2049
    • Campochiaro, P.A.1    Brown, D.M.2    Awh, C.C.3
  • 17
    • 84885022258 scopus 로고    scopus 로고
    • Long-term outcomes of ranibizumab therapy for diabetic macular edema: The 36-month results from two phase III trials: RISE and RIDE
    • Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013-2022.
    • (2013) Ophthalmology , vol.120 , Issue.10 , pp. 2013-2022
    • Brown, D.M.1    Nguyen, Q.D.2    Marcus, D.M.3
  • 18
    • 84911381185 scopus 로고    scopus 로고
    • Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
    • Moja L, Lucenteforte E, Kwag KH, et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2014;9:CD011230.
    • (2014) Cochrane Database Syst Rev , vol.9
    • Moja, L.1    Lucenteforte, E.2    Kwag, K.H.3
  • 19
    • 84958568980 scopus 로고    scopus 로고
    • Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: A systematic review and meta-analysis
    • Avery RL, Gordon GM. Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis. JAMA Ophthalmol. 2016;134(1):21-29.
    • (2016) JAMA Ophthalmol , vol.134 , Issue.1 , pp. 21-29
    • Avery, R.L.1    Gordon, G.M.2
  • 20
    • 84961924620 scopus 로고    scopus 로고
    • Re: Berg et al.: Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol (Ophthalmology 2015;122:146-52)
    • Avery RL. Re: Berg et al.: Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol (Ophthalmology 2015;122:146-52). Ophthalmology. 2016;123(2):e14-16.
    • (2016) Ophthalmology , vol.123 , Issue.2 , pp. e14-e16
    • Avery, R.L.1
  • 21
    • 84959361928 scopus 로고    scopus 로고
    • Risk of myocardial infarction and stroke with single or repeated doses of intravitreal bevacizumab in age-related macular degeneration
    • Etminan M, Maberley DA, Babiuk DW, Carleton BC. Risk of myocardial infarction and stroke with single or repeated doses of intravitreal bevacizumab in age-related macular degeneration. Am J Ophthalmol. 2016;163:53-58.
    • (2016) Am J Ophthalmol , vol.163 , pp. 53-58
    • Etminan, M.1    Maberley, D.A.2    Babiuk, D.W.3    Carleton, B.C.4
  • 22
    • 84908354473 scopus 로고    scopus 로고
    • Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema
    • Kiss S, Liu Y, Brown J, et al. Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema. Clin Ophthalmol. 2014;8:1611-1621.
    • (2014) Clin Ophthalmol , vol.8 , pp. 1611-1621
    • Kiss, S.1    Liu, Y.2    Brown, J.3
  • 23
    • 84908118639 scopus 로고    scopus 로고
    • Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema
    • Boyer DS, Yoon YH, Belfort R Jr., et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904-1914.
    • (2014) Ophthalmology , vol.121 , Issue.10 , pp. 1904-1914
    • Boyer, D.S.1    Yoon, Y.H.2    Belfort, R.3
  • 24
    • 84867099927 scopus 로고    scopus 로고
    • Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema
    • Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119(10):2125-2132.
    • (2012) Ophthalmology , vol.119 , Issue.10 , pp. 2125-2132
    • Campochiaro, P.A.1    Brown, D.M.2    Pearson, A.3
  • 26
    • 84920971127 scopus 로고    scopus 로고
    • Evaluation of compounded bevacizumab prepared for intravitreal injection
    • Yannuzzi NA, Klufas MA, Quach L, et al. Evaluation of compounded bevacizumab prepared for intravitreal injection. JAMA Ophthalmol. 2015;133(1):32-39.
    • (2015) JAMA Ophthalmol , vol.133 , Issue.1 , pp. 32-39
    • Yannuzzi, N.A.1    Klufas, M.A.2    Quach, L.3
  • 27
    • 84879798373 scopus 로고    scopus 로고
    • Streptococcus endophthalmitis outbreak after intravitreal injection of bevacizumab: One-year outcomes and investigative results
    • Goldberg RA, Flynn HW Jr., Miller D, Gonzalez S, Isom RF. Streptococcus endophthalmitis outbreak after intravitreal injection of bevacizumab: one-year outcomes and investigative results. Ophthalmology. 2013;120(7):1448-1453.
    • (2013) Ophthalmology , vol.120 , Issue.7 , pp. 1448-1453
    • Goldberg, R.A.1    Flynn, H.W.2    Miller, D.3    Gonzalez, S.4    Isom, R.F.5
  • 28
    • 84983761869 scopus 로고    scopus 로고
    • Cost effectiveness of aflibercept, bevacizumab, or ranibizumab for diabetic macular edema
    • February 24-27, Miami, FL
    • Jampol LM, Risse E, Hutton D, et al. Cost effectiveness of aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. Paper presented at: Macula Society Annual Meeting; February 24-27, 2016; Miami, FL.
    • (2016) Macula Society Annual Meeting
    • Jampol, L.M.1    Risse, E.2    Hutton, D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.